This article has Open Peer Review reports available.
Gastrointestinal stromal tumour of the duodenum in childhood: a rare case report
- Massimo Chiarugi†1Email author,
- Christian Galatioto†1,
- Piero Lippolis†1,
- Giuseppe Zocco†1 and
- Massimo Seccia†1
© Chiarugi et al; licensee BioMed Central Ltd. 2007
Received: 13 June 2006
Accepted: 09 May 2007
Published: 09 May 2007
Gastrointestinal stromal tumours (GISTs) are uncommon primary mesenchymal tumours of the gastrointestinal tract mostly observed in the adults. Duodenal GISTs are relatively rare in adults and it should be regarded as exceptional in childhood. In young patients duodenal GISTs may be a source of potentially lethal haemorrhage and this adds diagnostic and therapeutic dilemmas to the concern about the long-term outcome.
A 14-year-old boy was referred to our hospital with severe anaemia due to recurrent episodes of upper gastrointestinal haemorrhage. Endoscopy, small bowel series, scintigraphy and video capsule endoscopy previously done elsewhere were negative. Shortly after the admission, the patient underwent emergency surgery for severe recurrence of the bleeding. At surgery, a 4 cm solid mass arising from the wall of the fourth portion of the duodenum was identified. The invasion and the erosion of the duodenal mucosa was confirmed by intra-operative pushed duodenoscopy. The mass was resected by a full-thickness duodenal wall excision with adequate grossly free margins. Immunohistochemical analysis of the specimen revealed to be positive for CD117 (c-KIT protein) consistent with a diagnosis of GIST. The number of mitoses was < 5/50 HPF. Mutational analysis for c-KIT/PDGFRA tyrosine kinase receptor genes resulted in a wildtype pattern. The patient had an uneventful course and he has remained disease-free during two years of follow-up.
Duodenal GISTs in children are very rare and may present with massive bleeding. Cure can be achieved by complete surgical resection, but even in the low-aggressive tumours the long-term outcome may be unpredictable.
Gastrointestinal stromal tumours (GISTs) are uncommon mesenchymal tumours of the gastro-intestinal tract (GI) believed to originate from the interstitial cells of Cajal (ICC) . Likewise ICC, the GIST cells carry the receptor tyrosine kinase (KIT). Immunohistochemically the specific marker for KIT (CD117) is used to distinguish GIST from others spindle-cell tumours of the GI. Although a GIST may arise anywhere in the GI, stomach and small bowel are the most elective sites . It can be estimated that the frequency location of GISTs in the duodenum account approximately to 5% [3–5]. GISTs are far more common in adults, and over the age of 40. A report focused on the epidemiology of GISTs and including 1,458 cases found no patient below the age of 20 . Others large sample size retrospective studies confirm that GISTs are mostly observed in adults and are rare in children. Only 2.7% of GISTs of the stomach and 0.6% of GISTs of the small-bowel occur before the age of 21 years and the mean age of patients presenting with duodenal GISTs is over 50 [3–5]. Duodenal GISTs in children are extremely rare. We report a new clinical observation to enforce knowledge about GISTs of the duodenum in young patients.
The duodenal wall was carefully dissected free from the lower pancreatic border and from the superior mesenteric artery. Removal of the mass was then accomplished by a full-thickness excision of the anterior duodenal wall with adequate grossly free margins. The duodenal defect was over-sewn and covered by an omental patch.
Most GISTs arise in adults over 40 years of age . In the pediatric age group, GISTs occur in the sporadic form and in some cases are associated with Carney's triad or type 1 neurofibromatosis. Rare cases of familial GISts which carry a KIT or PDGFRa germline mutation have been also described [7, 8]. The duodenal localization of a GIST in children is however exceptional. Cypriano and Coll.  reported in 2004 a series of 7 pediatric patients affected by GIST: none of them originated from the duodenum. More recently, from a review of the English-language biomedical literature, Hayashi & Coll. found 25 children affected by GIST, none of them with a duodenal localization. Two further series of pediatric GISTs, each collecting five cases, failed to identify a duodenal localization [11, 12]. So far, the only previously described pediatric patient with a duodenal GIST is by Towu and Coll. that reported in two papers the case of a 7-year-old boy: bleeding was the clinical presentation and the tumour was successfully resected [13, 14]. Likewise in adults, duodenal GISTs in children may have an acute clinical onset, with bleeding as one of the most common complication. Endo-luminal bleeding is the expression of local invasion and erosion of the GI mucosa. For GISTs of the foregut, the identification of the source of bleeding may be easily performed by upper endoscopy whenever the tumor is located in the stomach or in the upper duodenum. On the other hand GISTs of the distal duodenum may remain undetected at endoscopy. Alternative diagnostic means for occult upper GI bleeding include duodenum series, US and computed tomography, video-capsule endoscopy, Tc99m scintigraphy and angiography. In the presented cases most of them resulted un-effective in making the diagnosis that was cleared only at surgery. Surgical removal of a duodenal GIST may be accomplished by several options, ranging from the minimal to outmost demolitive procedures. Local tumour excision , segmental duodenal resection [16–18] and pancreatoduodenectomy [19–21] have all been advocated, depending on the site and the size of the tumour and on the surrounding organs invasion. Total tumour resection is the standard of cure for GISTs. Nodes dissection is not recommended, because GISTs rarely metastasize to lymph nodes . In eligible patients, total resection of a duodenal GIST can be achieved by a simple excision procedure, that is effective in controlling the bleeding and in achieving cure. Children may benefit of advantages from lesser demolitive duodenal surgery. Treatment with imatinib, an inhibitor of receptor tyrosine kinases (RTKs), may be offered to pediatric patients with advanced GIST disease, not radically amenable by surgery. Several papers have reported a correlation between the nature of molecular alterations of KIT and PDGFRα and response to imatinib treatment [23–25]. In adults most GISTs are caused by mutations in the KIT or PDGFRα receptor tyrosine kinase genes and this make them amenable to therapy with imatinib. Thus, adult patients with unresectable or recurrent GIST have a better prognosis because the disease usually responds to therapy. In children genes mutations have been described in the rare cases of familial GISTs, but they do occur very rarely in sporadic GISTs [11, 12, 26]. Because most pediatric GISTs have KIT/PDGFRα wildtype patterns, these patients are expected to respond to imatinib treatment less well than adults do.
Complete surgical resection of GISTs seems however more likely in pediatric rather than in adult patients. In a paper presenting a series of pediatric patients with GIST and collecting data from literature, the rate of complete surgical resection was 80% (18 out 23 patients) and more than 90% of these patients survived with no evidence of recurrence . In adults, complete surgical resection of GISTs has been reported in 40% of cases . Moreover the recurrence of GISTs in adults ranges from 40 to 80% despite complete surgical resection of the primary tumor [22, 27]. These data suggest a more benign course for pediatric GISTs respect to adult cases.
According to the risk assessment criteria , the GIST of the presented case fell in to the low-risk of aggressive behaviour category (tumour size < 5 cm and mitotic counts < 5 mitotic figures per 50 HPF) and no chemotherapy after surgery was offered. Miettinen & Coll.  in a review of 156 duodenal GIST including adult and pediatric patients, found that 86% of those with a tumour > 5 cm with > 5 mitoses per 50 HPF died of disease, whereas no recurrence or metastases were seen in patients with tumour < 2 cm with < 5 mitoses/50 HPF. However, they occasionally observed the development of metastases even if the mitotic activity was < 5/50 HPF and the tumour size was < 5 cm. Thus, in young patients, even for the low-aggressive category of totally resected duodenal GISTs, the long-term outcome remains unpredictable. A long-term follow-up study is strongly advisable.
Written consent was obtained from the parents of the patient for publication of the patient's details.
- Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998, 152: 1259-1269.PubMedPubMed CentralGoogle Scholar
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BG, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Smookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.View ArticlePubMedGoogle Scholar
- Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumprs of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005, 29: 52-68. 10.1097/01.pas.0000146010.92933.de.View ArticlePubMedGoogle Scholar
- Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J: Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol. 2003, 27: 625-641. 10.1097/00000478-200305000-00006.View ArticlePubMedGoogle Scholar
- Miettinen M, Makhlouf H, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006, 30: 477-489. 10.1097/00000478-200604000-00008.View ArticlePubMedGoogle Scholar
- Tran T, Davila JA, El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005, 100: 162-168. 10.1111/j.1572-0241.2005.40709.x.View ArticlePubMedGoogle Scholar
- Beghini A, Tibiletti MG, Roversi G, Chiaravalli AM, Serio G, Capella C, Larizza L: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer. 2001, 92: 657-662. 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, Lenoir GM, Bressac-De Paillerets B: PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004, 126: 318-321. 10.1053/j.gastro.2003.10.079.View ArticlePubMedGoogle Scholar
- Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC: Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer. 2004, 101: 39-50. 10.1002/cncr.20352.View ArticlePubMedGoogle Scholar
- Hayashi Y, Okazaki T, Yamataka A, Yanai T, Yamashiro Y, Tsurumaru M, Kajiyama Y, Miyano T: Gastrointestinal stromal tumor in a child and review of the literature. Pediatr Surg Int. 2005, 21: 914-917. 10.1007/s00383-005-1511-9.View ArticlePubMedGoogle Scholar
- Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, Maki RG, Wexler RH, LaQuaglia MP, Besmer P, Antonescu CR: Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005, 27: 179-187. 10.1097/01.mph.0000157790.81329.47.View ArticlePubMedGoogle Scholar
- Price VE, Zielenska M, Chilton-MacNeill S, Smith CR, Pappo AS: Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer. 2005, 45: 20-24. 10.1002/pbc.20377.View ArticlePubMedGoogle Scholar
- Towu E, Stanton M: Gastrointestinal stromal tumor presenting with severe bleeding: a review of the molecular biology. Pediatr Surg Int. 2006, 22: 462-464. 10.1007/s00383-006-1636-5.View ArticlePubMedGoogle Scholar
- Hughes JA, Cook JV, Said A, Chong SK, Towu E, Reidy J: Gastrointestinal stromal tumour of the duodenum in a 7-year-old boy. Pediatr Radiol. 2004, 34: 1024-1027. 10.1007/s00247-004-1298-1.View ArticlePubMedGoogle Scholar
- Hellies R, Sulis R, Puliga A, Pala M, Pietrangeli M: GIST: surgical treatment of 34 cases. Tumori. 2003, 89: 133-134.PubMedGoogle Scholar
- D'Amato A, Brini A, Montesani C, Pronio A, Chessa A, Manzi F, Ribotta G: Gastrointestinal stromal tumors: a series of 23 surgically treated cases. Ann Ital Chir. 2001, 72: 175-180.PubMedGoogle Scholar
- Goh BK, Chow PK, Ong HS, Wong WK: Gastrointestinal stromal tumor involving the second and third portion of the duodenum: treatment by partial duodenectomy and Roux-en-Y duodenojejunostomy. J Surg Oncol. 2005, 91: 273-275. 10.1002/jso.20311.View ArticlePubMedGoogle Scholar
- Kurihara N, Kikuchi T, Tanabe M, Kumamoto Y, Tsuyuki A, Fujishiro Y, Otani Y, Kubota T, Kumai K, Kitajima M: Partial resection of the second portion of the duodenum for gastrointestinal stromal tumor after effective transarterial embolization. Int J Clin Oncol. 2005, 10: 433-437. 10.1007/s10147-005-0503-z.View ArticlePubMedGoogle Scholar
- Wellmann K, Gohla G, Wenk H: Malignant gastrointestinal stromal tumor (GIST) of papilla vateri: a rare tumor entity. Chirurg. 2004, 75: 196-99. 10.1007/s00104-003-0737-0.View ArticlePubMedGoogle Scholar
- Sakakima Y, Inoue S, Fujii T, Hatsuno T, Takeda S, Kaneko T, Nagasaka T, Nakao A: Emergency pylorus-preserving pancreatodudodenenctomy followed by second stage pancreatojejunostomy for a gastrointestinal tumor of the duodenum with an intratumoral gas figure: report of a case. Surg Today. 2004, 34: 701-705. 10.1007/s00595-004-2771-z.View ArticlePubMedGoogle Scholar
- Akkus MA, Kismet K, Adibelli MA, Pulat H: Case report: duodenal stromal tumor. Acta Gastroenterol Belg. 2005, 68 (1): 95-7.PubMedGoogle Scholar
- Joensuu H, Fletcher CD, Dimitrijevic S, Siberman S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002, 3: 655-664. 10.1016/S1470-2045(02)00899-9.View ArticlePubMedGoogle Scholar
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Meheren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21: 4342-4349. 10.1200/JCO.2003.04.190.View ArticlePubMedGoogle Scholar
- Debiec-Rychter M, Dumez H, Judson I, Wesag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hgemeijer A, van Glabbeke M, van Oosterom AT: EORTIC Sof Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTIC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004, 40: 689-695. 10.1016/j.ejca.2003.11.025.View ArticlePubMedGoogle Scholar
- Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004, 22: 3813-3825. 10.1200/JCO.2004.05.140.View ArticlePubMedGoogle Scholar
- Miettinen M, Lasota J, Sobin LH: Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005, 29: 1373-1381. 10.1097/01.pas.0000172190.79552.8b.View ArticlePubMedGoogle Scholar
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.